Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis C

Free Subscription Articles published in Eur J Gastroenterol Hepatol Retrieve available abstracts of 31 articles: HTML format

Single Articles

February 2023
1. IDENO N, Nozaki A, Chuma M, Ogushi K, et al
   Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection.
   Eur J Gastroenterol Hepatol. 2023;35:219-226.
   PubMed     Abstract available
   
   
   December 2022
2. LEE DU, Ponder R, Lee KJ, Yoo A, et al
   The nationwide trends in hospital admissions, deaths, and costs related to hepatitis C stratified by psychiatric disorders and substance use: an analysis of US hospitals between 2016 and 2019.
   Eur J Gastroenterol Hepatol. 2022 Dec 23. doi: 10.1097/MEG.0000000000002498.
   PubMed     Abstract available
   
   
   October 2022
3. YIBIRIN M, Hosry J, Yepez Guevara E, Granwehr BP, et al
   High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
   Eur J Gastroenterol Hepatol. 2022;34:1098-1101.
   PubMed     Abstract available
   
   
   May 2022
4. DOFFOEL M, Tripon S, Ernwein F, Chaffraix F, et al
   Changes in the profile and therapeutic care of people who use drugs with HCV mono-infection: a retrospective study between 2015 and 2019 from a monocentric tertiary referent center in France.
   Eur J Gastroenterol Hepatol. 2022;34:560-566.
   PubMed     Abstract available
   
   
   March 2022
5. TAHTASAKAL CA, Oncul A, Sevgi DY, Demirbas D, et al
   Fibrosis scores that can be used in follow-up of after direct-acting antiviral treatment: APRI, FIB-4, King score and GUCI.
   Eur J Gastroenterol Hepatol. 2022;34:308-315.
   PubMed     Abstract available
   
   
   February 2022
6. TOYODA H, Yasuda S, Shiota S, Kumada T, et al
   Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response.
   Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97088.
   PubMed     Abstract available
   
   
   December 2021
7. DOFFOEL M, Ernwein F, Chaffraix F, Haumesser L, et al
   Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants.
   Eur J Gastroenterol Hepatol. 2021 Dec 30. pii: 00042737-900000000-97102.
   PubMed     Abstract available
   
   
   
8. NG A
   Underdiagnosis of hepatitis C in the community: do not forget vulnerable populations.
   Eur J Gastroenterol Hepatol. 2021;33.
   PubMed    
   
   
   
9. NG A
   Hepatocellular carcinoma recurrence after directly-acting antiviral therapy: caution with hepatitis C.
   Eur J Gastroenterol Hepatol. 2021;33.
   PubMed    
   
   
   
10. BASSO M, Zago D, Pozzetto I, Parisi SG, et al
    Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    
    
    
    September 2021
11. EL KASSAS M, Abdeen N, Omran D, Alboraie M, et al
    Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Sep 21. pii: 00042737-900000000-97142.
    PubMed     Abstract available
    
    
    July 2021
12. ALEM SA, Eletreby R, Abdellatif Z, Ramadan A, et al
    Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jul 6. pii: 00042737-900000000-97183.
    PubMed     Abstract available
    
    
    
13. EL RAY A, Fouad R, ElMakhzangy H, El Beshlawy M, et al
    Characterizing a cohort of Egyptian patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2021;33:1023-1028.
    PubMed     Abstract available
    
    
    April 2021
14. HAYES KN, Burkard T, Weiler S, Tadrous M, et al
    Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
    Eur J Gastroenterol Hepatol. 2021 Apr 21. pii: 00042737-900000000-97232.
    PubMed     Abstract available
    
    
    
15. YEO YH, Kam LY, Le MH, Jeong D, et al
    A population-based US study of hepatitis C diagnosis rate.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97245.
    PubMed     Abstract available
    
    
    
16. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication.
    Eur J Gastroenterol Hepatol. 2021 Apr 9. pii: 00042737-900000000-97256.
    PubMed     Abstract available
    
    
    March 2021
17. SERWAH MA, Omar SA, Khedr MS, Abdel-Hamid AES, et al
    Occurrence and clinical characteristics of occult hepatitis C virus infection in hemodialysis units at Ismailia, Egypt.
    Eur J Gastroenterol Hepatol. 2021 Mar 12. pii: 00042737-900000000-97270.
    PubMed     Abstract available
    
    
    February 2021
18. SAHIN M, Sucu P, Serin E, Yetim A, et al
    Serum fibrosis markers could aid in the prediction of factor for successful oral antiviral treatment in hepatitis C.
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97302.
    PubMed     Abstract available
    
    
    
19. SAUD LRC, Chagas AL, Maccali C, Pinto PVA, et al
    Hepatocellular carcinoma in patients coinfected with hepatitis B or C and HIV: more aggressive tumor behavior?
    Eur J Gastroenterol Hepatol. 2021 Feb 5. pii: 00042737-900000000-97300.
    PubMed     Abstract available
    
    
    January 2021
20. EL-NAHAAS SM, Rady NH, Malek S, Serag K, et al
    Changes in serum interferon-gamma-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents.
    Eur J Gastroenterol Hepatol. 2021 Jan 18. pii: 00042737-900000000-97309.
    PubMed     Abstract available
    
    
    
21. EL KASSAS M, Alboraie M, El-Sayed M, Elbehiry S, et al
    Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jan 14. doi: 10.1097/MEG.0000000000002043.
    PubMed     Abstract available
    
    
    
22. YILMAZ B, Kayadibi H, Yeniova AO, Koseoglu H, et al
    The age, bilirubin and albumin (ABA) index: a novel noninvasive index for predicting liver fibrosis in patients with chronic hepatitis C infection.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available
    
    
    
23. PESTANA NF, Equi CMA, Gomes CP, Cardoso AC, et al
    Aminotransferase-to-platelet ratio index and Fibrosis-4 index score predict hepatic fibrosis evaluated by transient hepatic elastography in hepatitis C virus-infected hemodialysis patients.
    Eur J Gastroenterol Hepatol. 2021;Publish Ahead of Print.
    PubMed     Abstract available
    
    
    November 2020
24. LASHEN SA, Metawea MI, Shaaban A
    Direct antiviral drugs in the treatment of hepatitis C-infected rheumatoid arthritis Egyptian cohort: safety and clinical impact.
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002015.
    PubMed     Abstract available
    
    
    
25. RIAL-CRESTELO D, Sepulveda MA, Gonzalez-Gasca FJ, Geijo-Martinez P, et al
    Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018).
    Eur J Gastroenterol Hepatol. 2020 Nov 30. doi: 10.1097/MEG.0000000000002012.
    PubMed     Abstract available
    
    
    
26. LITHY RM, Elbaz T, H Abdelmaksoud A, M Nabil M, et al
    Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000001972.
    PubMed     Abstract available
    
    
    
27. RUIZ I, Fourati S, Ahmed-Belkacem A, Rodriguez C, et al
    Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.
    Eur J Gastroenterol Hepatol. 2020 Nov 17. doi: 10.1097/MEG.0000000000002003.
    PubMed     Abstract available
    
    
    October 2020
28. OMRAN M, Fouda M, Abdelwahab AO, Nabeel MM, et al
    P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2020 Oct 16. doi: 10.1097/MEG.0000000000001962.
    PubMed     Abstract available
    
    
    August 2020
29. BEYAN C, Beyan E
    Mean platelet volume to platelet ratio may not be reliable to determine the severity of fibrosis in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:1067.
    PubMed    
    
    
    
30. ELSADEK HM, Abdelbaser ES, Emara MH, Soliman HH, et al
    Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    Eur J Gastroenterol Hepatol. 2020;32:1046-1053.
    PubMed     Abstract available
    
    
    February 2020
31. PERISETTI A, Laoveeravat P, Inamdar S, Tharian B, et al
    Hepatitis E virus infection in liver transplant recipients: a descriptive literature review.
    Eur J Gastroenterol Hepatol. 2020 Feb 21. doi: 10.1097/MEG.0000000000001682.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: